Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal?
Huntington's disease is a progressive neurodegenerative disorder caused by mutation of the huntingtin (HTT) gene, leading to the breakdown of brain cells. It is characterized by uncontrolled movements (chorea), cognitive decline, and psychiatric disturbances.
The study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p<0.0001) at Week 12 and favorable safety and tolerability. In addition, the 12-month data from the Stage 2 patients are consistent with the previously reported dose-dependent lowering of HTT protein and dose-dependent trends across clinical scales.
Also Read: European Commission Declines To Renew Marketing Authorization Of Translarna Duchenne Muscular Disorder
'We look forward to discussions on the next development and regulatory steps, including the potential for accelerated approval as we work to potentially bring the first disease-modifying therapy...,' said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.
Results from the full 12-month cohort demonstrate dose-dependent lowering in blood HTT levels, with 23% at the 5mg dose level for both Stage 2 and 3 patients and 39% and 36% at the 10mg dose level for Stage 2 and 3 patients, respectively. For Stage 2 patients, there were dose-dependent trends of benefit on clinical scales, including the Composite Unified Huntington's Disease Rating Scale (cUHDRS) and Total Motor Score (TMS) subscale.
For Stage 3 patients, trends favored the 5mg dose group relative to placebo but not the 10mg dose group, suggesting that treatment effect may differ in Stage 3 patients relative to Stage 2 patients. It seems investors are reacting to this as the stock is trading almost 20% lower during the premarket session.
PTC518 showed a favorable safety and tolerability profile for all dose levels and disease stages with no treatment-related serious adverse events or neurofilament light chain protein (NfL) spikes.
In addition, 24-month treatment data from the patients on whom data were shared last year (N=21) demonstrate signals of dose-dependent trends on the cUHDRS, Total Function Capacity (TFC), and Symbol Digit Modalities Test (SDMT) subscales when compared to a propensity-matched natural history cohort from the ENROLL-HD Registry.
At Month 24, there was also a dose-dependent lowering of plasma NfL from a baseline of -8.9% (nominal p=0.12) for the 5mg dose level and -14% (nominal p=0.03) for the 10mg dose level.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 hours ago
- Yahoo
Pardons, positions and power: Trump's donor list raises questions about pay-for-access in his administration
A new financial disclosure from a super PAC supporting President Donald Trump contains the name of the deep-pocket donors who have gained access to the White House. MAGA Inc.'s donor list includes Trump appointees, a mom who managed to get Trump to pardon her son, and cryptocurrency traders, according to a new report by the New York Times. The super PAC managed to pull some major donations for the president; according to the disclosure, MAGA Inc. raised more than $177 million for Trump since January. Some names on the list wound up working for Trump in his administration. Anjani Sinha, a friend of Trump's, was nominated to be the ambassador to Singapore. He donated $1 million to MAGA Inc. He hasn't been approved for the position yet, possibly because he struggled to answer questions about Singapore during his confirmation hearing. Cody Campbell, who is now on Trump's Council on Sports, Fitness, and Nutrition, donated half a million dollars to the super PAC. Josh Lobel, now sitting on Trump's Intelligence Advisory Board, donated $250,000. Several major donors are tied to the crypto industry, which has by and large found a friendly ally in Trump. According to the Times, Trump's inaugural committee raised an enormous $239 million, with approximately $18 million of that coming from crypto-related donors. According to the filing, donors working in cryptocurrencies accounted for $45 million of the donations reported through MAGA Inc. One donor alone — crypto entrepreneur Eric Schiermeyer — donated $1 million, and was given the chance to have dinner with Trump in Mar-a-Lago in March. The pair didn't just eat and chat — during the dinner, Schiermeyer apparently pitched Trump on an idea for a cryptocurrency called the "USA Token" that would be doled out to Americans for use in transactions. He reportedly wanted a government contract for his company to handle the task, according to the Times' reporting. He told the paper that he managed to get his idea in front of Trump face-to-face, so he considers it a win. 'I was able to say my piece, and the idea is clearly making the rounds, so mission accomplished from my view.' he told the Times. And then there's Elizabeth Fago, who handed over $1 million to MAGA Inc. and got herself a dinner with Trump. Three weeks later, her son, Paul Walczak, who pleaded guilty to tax fraud, was pardoned. A White House spokesperson who talked to the Times anonymously said that Fago's words, rather than her cash, convinced the president to give her son a break. 'He spoke directly to a mother who pleaded for her son, and when you're talking to a mother pleading for her son, that's a pretty powerful thing,' the source reportedly said. The Independent has requested comment from The White House. According to MAGA Inc., all of the apparent benefits that come along with shoveling money at Trump are just a coincidence. It told the Times that Trump doesn't treat donors any different from normal Americans. 'President Trump values his supporters and donors, but unlike politicians before him, he cannot be bought and works toward the best interest of the country,' it told the paper.
Yahoo
18 hours ago
- Yahoo
Pardons, positions and power: Trump's donor list raises questions about pay-for-access in his administration
A new financial disclosure from a super PAC supporting President Donald Trump contains the name of the deep-pocket donors who have gained access to the White House. MAGA Inc.'s donor list includes Trump appointees, a mom who managed to get Trump to pardon her son, and cryptocurrency traders, according to a new report by the New York Times. The super PAC managed to pull some major donations for the president; according to the disclosure, MAGA Inc. raised more than $177 million for Trump since January. Some names on the list wound up working for Trump in his administration. Anjani Sinha, a friend of Trump's, was nominated to be the ambassador to Singapore. He donated $1 million to MAGA Inc. He hasn't been approved for the position yet, possibly because he struggled to answer questions about Singapore during his confirmation hearing. Cody Campbell, who is now on Trump's Council on Sports, Fitness, and Nutrition, donated half a million dollars to the super PAC. Josh Lobel, now sitting on Trump's Intelligence Advisory Board, donated $250,000. Several major donors are tied to the crypto industry, which has by and large found a friendly ally in Trump. According to the Times, Trump's inaugural committee raised an enormous $239 million, with approximately $18 million of that coming from crypto-related donors. According to the filing, donors working in cryptocurrencies accounted for $45 million of the donations reported through MAGA Inc. One donor alone — crypto entrepreneur Eric Schiermeyer — donated $1 million, and was given the chance to have dinner with Trump in Mar-a-Lago in March. The pair didn't just eat and chat — during the dinner, Schiermeyer apparently pitched Trump on an idea for a cryptocurrency called the "USA Token" that would be doled out to Americans for use in transactions. He reportedly wanted a government contract for his company to handle the task, according to the Times' reporting. He told the paper that he managed to get his idea in front of Trump face-to-face, so he considers it a win. 'I was able to say my piece, and the idea is clearly making the rounds, so mission accomplished from my view.' he told the Times. And then there's Elizabeth Fago, who handed over $1 million to MAGA Inc. and got herself a dinner with Trump. Three weeks later, her son, Paul Walczak, who pleaded guilty to tax fraud, was pardoned. A White House spokesperson who talked to the Times anonymously said that Fago's words, rather than her cash, convinced the president to give her son a break. 'He spoke directly to a mother who pleaded for her son, and when you're talking to a mother pleading for her son, that's a pretty powerful thing,' the source reportedly said. The Independent has requested comment from The White House. According to MAGA Inc., all of the apparent benefits that come along with shoveling money at Trump are just a coincidence. It told the Times that Trump doesn't treat donors any different from normal Americans. 'President Trump values his supporters and donors, but unlike politicians before him, he cannot be bought and works toward the best interest of the country,' it told the paper.
Business Wire
a day ago
- Business Wire
RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17, 2024 and May 26, 2025. Rocket Pharmaceuticals is a fully integrated, late-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) RP-A501 was less effective than defendants had led investors to believe; (2) to increase its effectiveness, Rocket Pharmaceuticals amended RP-A501's clinical trial protocol by introducing a novel immunomodulatory agent; (3) the foregoing increased the risk that patients would suffer from a Serious Adverse Event ('SAE'); (4) accordingly, RP-A501's safety, as well as its clinical, regulatory, and commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Rocket Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by August 11, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
